<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "6: highly competitive healthcare industry", fill: "#85bb65"},
{source: "6: highly competitive healthcare industry", target: "6: compete successfully", fill: "#85bb65"},
{source: "6: highly competitive healthcare industry", target: "9: competitors", fill: "#fff8e7"},
{source: "9: competitors", target: "9: contact lens", fill: "#fff8e7"},
{source: "9: contact lens", target: "9: substantially greater", fill: "#fff8e7"},
{source: "9: substantially greater", target: "9: financial resources larger research", fill: "#fff8e7"},
{source: "9: financial resources larger research", target: "9: development budgets larger sales", fill: "#fff8e7"},
{source: "9: development budgets larger sales", target: "9: forces greater market penetration", fill: "#fff8e7"},
{source: "9: forces greater market penetration", target: "9: larger manufacturing volumes than", fill: "#fff8e7"},
{source: "9: larger manufacturing volumes than", target: "9: specialty contact lens", fill: "#fff8e7"},
{source: "9: specialty contact lens", target: "9: competitive", fill: "#fff8e7"},
{source: "9: competitive", target: "9: products newer materials plus", fill: "#fff8e7"},
{source: "9: products newer materials plus", target: "9: lens care products", fill: "#fff8e7"},
{source: "9: lens care products", target: "9: ophthalmic pharmaceuticals which", fill: "#fff8e7"},
{source: "9: ophthalmic pharmaceuticals which", target: "9: may give them", fill: "#fff8e7"},
{source: "9: may give them", target: "9: competitive advantage", fill: "#fff8e7"},
{source: "9: competitors", target: "10: Moreover ", fill: "#e0b0ff"},
{source: "10: Moreover ", target: "10: manufacture", fill: "#e0b0ff"},
{source: "10: Moreover ", target: "13: significant", fill: "#af4035"},
{source: "13: significant", target: "13: costs per lens will depend", fill: "#af4035"},
{source: "13: costs per lens will depend", target: "13: increase sales volume", fill: "#af4035"},
{source: "13: increase sales volume", target: "13: production capacity", fill: "#af4035"},
{source: "13: significant", target: "14: competitive pressures", fill: "#c19a6b"},
{source: "14: competitive pressures", target: "14: timely manner could", fill: "#c19a6b"},
{source: "14: timely manner could", target: "14: financial condition", fill: "#c19a6b"},
{source: "14: financial condition", target: "14: operations", fill: "#c19a6b"},
{source: "14: competitive pressures", target: "24: new products will successfully compete", fill: "#614051"},
{source: "24: new products will successfully compete", target: "24: expense involved", fill: "#614051"},
{source: "24: expense involved", target: "24: development", fill: "#614051"},
{source: "24: development", target: "24: regulatory approval", fill: "#614051"},
{source: "24: new products will successfully compete", target: "42: International ", fill: "#fba0e3"},
{source: "42: International ", target: "42: operations", fill: "#fba0e3"},
{source: "42: operations", target: "42: numerous additional risks", fill: "#fba0e3"},
{source: "42: numerous additional risks", target: "42: longer payment cycles than customers", fill: "#fba0e3"},
{source: "42: longer payment cycles than customers", target: "42: United States ", fill: "#fba0e3"},
{source: "42: United States ", target: "42: comply with", fill: "#fba0e3"},
{source: "42: comply with", target: "42: United States Department of Commerce ", fill: "#fba0e3"},
{source: "42: United States Department of Commerce ", target: "42: fines andor penalties", fill: "#fba0e3"},
{source: "42: fines andor penalties", target: "42: foreign countries", fill: "#fba0e3"},
{source: "42: foreign countries", target: "42: requirements", fill: "#fba0e3"},
{source: "42: requirements", target: "42: restrictions", fill: "#fba0e3"},
{source: "42: restrictions", target: "42: difficult", fill: "#fba0e3"},
{source: "42: difficult", target: "42: foreign regulatory", fill: "#fba0e3"},
{source: "42: foreign regulatory", target: "42: general economic", fill: "#fba0e3"},
{source: "42: general economic", target: "42: political conditions", fill: "#fba0e3"},
{source: "42: political conditions", target: "42: growth strategy", fill: "#fba0e3"},
{source: "42: growth strategy", target: "42: organization spread", fill: "#fba0e3"},
{source: "42: organization spread", target: "42: foreign governments may adopt regulations", fill: "#fba0e3"},
{source: "42: foreign governments may adopt regulations", target: "42: indirect adverse impact on", fill: "#fba0e3"},
{source: "42: indirect adverse impact on", target: "42: opportunities", fill: "#fba0e3"},
{source: "42: opportunities", target: "42: difficulty enforcing agreements", fill: "#fba0e3"},
{source: "42: difficulty enforcing agreements", target: "42: collecting receivables", fill: "#fba0e3"},
{source: "42: collecting receivables", target: "42: foreign legal systems", fill: "#fba0e3"},
{source: "42: foreign legal systems", target: "42: fluctuations", fill: "#fba0e3"},
{source: "42: fluctuations", target: "42: currency exchange rates could adversely affect", fill: "#fba0e3"},
{source: "42: currency exchange rates could adversely affect", target: "42: difficulty enforcing intellectual property rights", fill: "#fba0e3"},
{source: "42: difficulty enforcing intellectual property rights", target: "42: difficulty gaining market", fill: "#fba0e3"},
{source: "42: difficulty gaining market", target: "42: countries such as", fill: "#fba0e3"},
{source: "42: countries such as", target: "42: or other Japan ", fill: "#fba0e3"},
{source: "42: or other Japan ", target: "42: regulatory restrictions", fill: "#fba0e3"},
{source: "42: regulatory restrictions", target: "42: customer preferences", fill: "#fba0e3"},
{source: "42: customer preferences", target: "42: enter new markets such as", fill: "#fba0e3"},
{source: "42: enter new markets such as", target: "42: China India ", fill: "#fba0e3"},
{source: "42: China India ", target: "42: acceptance", fill: "#fba0e3"},
{source: "42: acceptance", target: "42: distribution", fill: "#fba0e3"},
{source: "42: International ", target: "START_HERE", fill: "#fba0e3"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Environmental Services</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Electronic Equipment and Instruments</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Material Aid</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Riot</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Rally support</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Promise policy support</td>
    </tr>
    <tr>
      <td>Travel to meet</td>
    </tr>
    <tr>
      <td>Propose</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Consult</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Automotive_industry">Automotive industry</a></td>
      <td>The automotive industry comprises a wide range of companies and organizations involved in the design, development, manufacturing, marketing, and selling of motor vehicles. It is one of the world's largest industries by revenue (from 16 % such as in France up to 40 % to countries like Slovakia).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_statement">Financial statement</a></td>
      <td>Financial statements (or financial reports) are formal records of the financial activities and position of a business, person, or other entity.\nRelevant financial information is presented in a structured manner and in a form which is easy to understand.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_figures">Significant figures</a></td>
      <td>Significant figures (also known as the significant digits, precision or resolution) of a number in positional notation are digits in the number that are reliable and necessary to indicate the quantity of something.\nIf a number expressing the result of a measurement (e.g., length, pressure, volume, or mass) has more digits than the number of digits allowed by the measurement resolution, then only as many digits as allowed by the measurement resolution are reliable, and so only these can be significant figures.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_other">Significant other</a></td>
      <td>The term significant other (SO) has different uses in psychology and in colloquial language. Colloquially "significant other" is used as a gender-neutral term for a person's partner in an intimate relationship without disclosing or presuming anything about marital status, relationship status, gender identity, or sexual orientation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bit_numbering">Bit numbering</a></td>
      <td>In computing, bit numbering is the convention used to identify the bit positions in a binary number.\n\n\n== Bit significance and indexing ==\n\nIn computing, the least significant bit (LSB) is the bit position in a binary integer representing the binary 1s place of the integer.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Statistical_significance">Statistical significance</a></td>
      <td>In statistical hypothesis testing, a result has statistical significance when it is very unlikely to have occurred given the null hypothesis. More precisely, a study's defined significance level, denoted by \n  \n    \n      \n        α\n      \n    \n    {\displaystyle \alpha }\n  , is the probability of the study rejecting the null hypothesis, given that the null hypothesis is true; and the p-value of a result, \n  \n    \n      \n        p\n      \n    \n    {\displaystyle p}\n  , is the probability of obtaining a result at least as extreme, given that the null hypothesis is true.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_form">Significant form</a></td>
      <td>Significant form refers to an aesthetic theory developed by English art critic Clive Bell which specified a set of criteria for what qualified as a work of art.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_Others">Significant Others</a></td>
      <td>The term significant other (SO) has different uses in psychology and in colloquial language. Colloquially "significant other" is used as a gender-neutral term for a person's partner in an intimate relationship without disclosing or presuming anything about marital status, relationship status, gender identity, or sexual orientation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Simpsons">The Simpsons</a></td>
      <td>The Simpsons is an American animated sitcom created by Matt Groening for the Fox Broadcasting Company. The series is a satirical depiction of American life, epitomized by the Simpson family, which consists of Homer, Marge, Bart, Lisa, and Maggie.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Internet">Internet</a></td>
      <td>In finance and economics, interest is payment from a borrower or deposit-taking financial institution to a lender or depositor of an amount above repayment of the principal sum (that is, the amount borrowed), at a particular rate. It is distinct from a fee which the borrower may pay the lender or some third party.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_condition_report">Financial condition report</a></td>
      <td>In accounting, a financial condition report (FCR) is a report on the solvency condition of an insurance company that takes into account both the current financial status, as reflected in the balance sheet, and an assessment of the ability of the company to survive future risk scenarios. Risk assessment in an FCR involves dynamic solvency testing, a type of dynamic financial analysis that simulates management response to risk scenarios, to test whether a company could remain solvent in the face of deteriorating economic conditions or major disasters.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_ratio">Financial ratio</a></td>
      <td>A financial ratio or accounting ratio is a relative magnitude of two selected numerical values taken from an enterprise's financial statements. Often used in accounting, there are many standard ratios used to try to evaluate the overall financial condition of a corporation or other organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_law">Financial law</a></td>
      <td>Financial law is the law and regulation of the insurance, derivatives, commercial banking, capital markets and investment management sectors. Understanding Financial law is crucial to appreciating the creation and formation of banking and financial regulation, as well as the legal framework for finance generally.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Trustmark_(bank)">Trustmark (bank)</a></td>
      <td>Trustmark is a commercial bank and financial services company headquartered in Jackson, Mississippi, United States, with subsidiaries Trustmark National Bank, Trustmark Investment Advisors, and Fisher Brown Bottrell Insurance. The bank's initial predecessor, The Jackson Bank, was chartered by the State of Mississippi in 1889.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_analysis">Financial analysis</a></td>
      <td>Financial analysis (also referred to as financial statement analysis or accounting analysis or Analysis of finance) refers to an assessment of the viability, stability, and profitability of a business, sub-business or project. \nIt is performed by professionals who prepare reports using ratios and other techniques, that make use of information taken from financial statements and other reports.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Federal_takeover_of_Fannie_Mae_and_Freddie_Mac">Federal takeover of Fannie Mae and Freddie Mac</a></td>
      <td>In September 2008 the Federal Housing Finance Agency (FHFA) announced that it would take over the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac). Both government-sponsored enterprises, which finance home mortgages in the United States by issuing bonds, had become illiquid as the market for those bonds collapsed in the subprime mortgage crisis.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Surgery">Surgery</a></td>
      <td>Surgery is a medical or dental specialty that uses operative manual and instrumental techniques on a person to investigate or treat a pathological condition such as a disease or injury, to help improve bodily function, appearance, or to repair unwanted ruptured areas.\nThe act of performing surgery may be called a surgical procedure, operation, or simply "surgery".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_(mathematics)">Operation (mathematics)</a></td>
      <td>In mathematics, an operation is a function which takes zero or more input values (called operands) to a well-defined output value. The number of operands (also known as arguments) is the arity of the operation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Requirement">Requirement</a></td>
      <td>In product development and process optimization, a requirement is a singular documented physical or functional need that a particular design, product or process aims to satisfy. It is commonly used in a formal sense in engineering design, including for example in systems engineering, software engineering, or enterprise engineering.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Non-functional_requirement">Non-functional requirement</a></td>
      <td>In systems engineering and requirements engineering, a non-functional requirement (NFR) is a requirement that specifies criteria that can be used to judge the operation of a system, rather than specific behaviours. They are contrasted with functional requirements that define specific behavior or functions.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Requirements_engineering">Requirements engineering</a></td>
      <td>Requirements engineering (RE) is the process of defining, documenting, and maintaining requirements in the engineering design process. It is a common role in systems engineering and software engineering.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Requirements_analysis">Requirements analysis</a></td>
      <td>In systems engineering and software engineering, requirements analysis focuses on the tasks that determine the needs or conditions to meet the new or altered product or project, taking account of the possibly conflicting requirements of the various stakeholders, analyzing, documenting, validating and managing software or system requirements.Requirements analysis is critical to the success or failure of a systems or software project. The requirements should be documented, actionable, measurable, testable, traceable, related to identified business needs or opportunities, and defined to a level of detail sufficient for system design.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Visa_requirements_for_United_States_citizens">Visa requirements for United States citizens</a></td>
      <td>As of 25 February 2022, Holders of a United States passport could travel to 186 countries and territories without a travel visa, or with a visa on arrival. The United States passport currently ranks 6th in terms of travel freedom (tied with the passports of Czech Republic, Greece, Malta, Norway, and the UK) according to the Henley Passport Index.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Age_of_candidacy">Age of candidacy</a></td>
      <td>Age of candidacy is the minimum age at which a person can legally hold certain elected government offices. In many cases, it also determines the age at which a person may be eligible to stand for an election or be granted ballot access.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Market_requirements_document">Market requirements document</a></td>
      <td>A market requirements document (MRD) in project management and systems engineering, is a document that expresses the customer's wants and needs for the product or service.\nIt is typically written as a part of product marketing or product management.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Requirements_elicitation">Requirements elicitation</a></td>
      <td>In requirements engineering, requirements elicitation is the practice of researching and discovering the requirements of a system from users, customers, and other stakeholders. The practice is also sometimes referred to as "requirement gathering".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Visa_requirements_for_British_citizens">Visa requirements for British citizens</a></td>
      <td>Visa requirements for British citizens are administrative entry restrictions by the authorities of other states placed on citizens of the United Kingdom. As of 30 April 2022, British citizens had visa-free or visa on arrival access to 187 countries and territories, ranking their passport 5th in terms of travel freedom (tied with France, Ireland and Portugal) according to the Henley Passport Index.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/System_requirements_specification">System requirements specification</a></td>
      <td>A System Requirements Specification (SyRS) (abbreviated SysRS when need to be distinct from a software requirements specification (SRS)) is a structured collection of information that embodies the requirements of a system.A business analyst (BA), sometimes titled system analyst, is responsible for analyzing the business needs of their clients and stakeholders to help identify business problems and propose solutions. Within the systems development life cycle domain, the BA typically performs a liaison function between the business side of an enterprise and the information technology department or external service providers.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>COOPER COMPANIES INC      Item 1A <font color="blue">Risk Factors</font></td>
    </tr>
    <tr>
      <td>Our business <font color="blue">faces <font color="blue">significant</font> risks</font></td>
    </tr>
    <tr>
      <td>These risks include those described     below and may include <font color="blue">additional risks</font> and <font color="blue">uncertainties</font> not <font color="blue">presently known</font>     to  us  or  that we currently deem immaterial</td>
    </tr>
    <tr>
      <td>Our business, financial     condition and results of <font color="blue"><font color="blue">operations</font> could</font> be <font color="blue"><font color="blue">materially</font> <font color="blue">adversely</font> affected</font>     by  any  of these risks, and the <font color="blue">trading prices</font> of our <font color="blue">common stock</font> or     convertible  <font color="blue">debentures</font>  could  decline</td>
    </tr>
    <tr>
      <td>These <font color="blue">risks should</font> be read in     <font color="blue">conjunction with</font> the other information in this report</td>
    </tr>
    <tr>
      <td>Risks Relating to Our Business          We operate in the <font color="blue">highly <font color="blue">competitive</font> <font color="blue">healthcare industry</font></font> and there can be no     assurance that we will be able to <font color="blue">compete <font color="blue">successfully</font></font></td>
    </tr>
    <tr>
      <td>Each of our <font color="blue">businesses</font> operates within a highly <font color="blue">competitive</font> <font color="blue">environment</font></td>
    </tr>
    <tr>
      <td>In     our  soft  contact  lens  segment,  CVI <font color="blue">faces intense competition from</font>     <font color="blue">competitors</font>’ products, including <font color="blue">newer silicone hydrogel <font color="blue">contact lens</font>es</font>, and     <font color="blue">may face increasing competition as</font> other <font color="blue"><font color="blue">new products</font> enter</font> the market</td>
    </tr>
    <tr>
      <td>Our     major <font color="blue">competitors</font> in the <font color="blue">contact lens</font> business have <font color="blue"><font color="blue">substantially</font> greater</font>     financial resources, larger research and <font color="blue">development</font> budgets, larger sales     forces, greater market penetration and <font color="blue">larger <font color="blue">manufacturing</font> volumes than</font>     CVI         Our  major  <font color="blue">competitors</font>  in  the specialty <font color="blue">contact lens</font> business offer     <font color="blue">competitive</font>  products, newer materials plus a variety of other eyecare     products, including <font color="blue">lens care products</font> and ophthalmic pharmaceuticals, which     <font color="blue">may give them</font> a <font color="blue">competitive</font> advantage in marketing their lenses</td>
    </tr>
    <tr>
      <td>Moreover,     newer <font color="blue">silicone hydrogel lenses</font> may gain market <font color="blue">acceptance</font> in the specialty     lens business before we are able to <font color="blue">manufacture</font> in volume and market our own     <font color="blue">competitive</font> silicone hydrogel specialty products, <font color="blue">which could</font> erode our     market share and margins</td>
    </tr>
    <tr>
      <td>The market for our non-specialty, commodity <font color="blue">contact lens</font>es is <font color="blue">also intensely</font>     <font color="blue">competitive</font> and is <font color="blue"><font color="blue">characterized by</font> declining prices</font> for many <font color="blue">older product</font>     lines and <font color="blue">growing demand</font> for <font color="blue">newer silicone hydrogel based products</font></td>
    </tr>
    <tr>
      <td>Our     ability to respond to these <font color="blue">competitive</font> pressures will depend on our ability     to decrease our costs and maintain gross margins and operating results and     to introduce our own <font color="blue">silicone hydrogel products on</font> a <font color="blue">timely basis</font> and to     achieve  <font color="blue"><font color="blue">manufacturing</font> efficiencies</font> for <font color="blue">such products</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">significant</font>     decrease in our <font color="blue">costs per lens will depend</font>, in part, on our ability to     <font color="blue">increase sales volume</font> and <font color="blue">production capacity</font></td>
    </tr>
    <tr>
      <td>Our failure to respond to     <font color="blue">competitive</font> pressures in a <font color="blue">timely manner could</font> have a material adverse     effect on our business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>To a lesser extent, CVI also competes with <font color="blue">manufacture</font>rs of <font color="blue">eyeglasses</font> and     other forms of <font color="blue">vision correction</font> including <font color="blue">ophthalmic surgery</font></td>
    </tr>
    <tr>
      <td>There can be     no assurance that we will not <font color="blue">encounter increased competition</font> in the future,     or that a <font color="blue">successful entry into</font> CVI’s higher-margin specialty lens segments     by a <font color="blue">larger competitor would</font> not have a material adverse effect on our     business, <font color="blue">financial condition</font> or results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In the women’s healthcare segment, <font color="blue">competitive</font> factors include <font color="blue">technological</font>     and scientific advances, product quality, price and <font color="blue">effective</font> <font color="blue">communication</font>     of product information to physicians and hospitals</td>
    </tr>
    <tr>
      <td><font color="blue">CooperSurgical </font>competes     with a number of <font color="blue">manufacture</font>rs in each of its <font color="blue">niche markets</font>, some of which     have <font color="blue"><font color="blue">substantially</font> greater</font> financial and <font color="blue">personnel resources</font> and sell a much     <font color="blue">broader range</font> of products, which <font color="blue">may give them</font> an advantage in marketing     <font color="blue">competitive</font> products</td>
    </tr>
    <tr>
      <td>17     ______________________________________________________________________    [38]Table of <font color="blue">Contents       </font>Product innovations are important in the industry in which we operate, and     we face the risk of <font color="blue">product obsolescence</font></td>
    </tr>
    <tr>
      <td>Product innovations are important in the <font color="blue">contact lens</font> business in which CVI     competes and in the <font color="blue">niche areas</font> of the <font color="blue">healthcare industry</font> in which CSI     competes</td>
    </tr>
    <tr>
      <td>We have not <font color="blue"><font color="blue">historically</font> allocated</font> substantial resources to new     product <font color="blue">development</font>, but rather have purchased, leveraged or licensed the     <font color="blue"><font color="blue">technology</font> <font color="blue">development</font>s</font> of others</td>
    </tr>
    <tr>
      <td>With the <font color="blue">acquisition</font> of Ocular, we have     begun to invest more in <font color="blue">new product <font color="blue">development</font></font>, including the <font color="blue">development</font>     of silicone hydrogel based <font color="blue">contact lens</font>es</td>
    </tr>
    <tr>
      <td>Although our focus is on products     that will be <font color="blue">marketable immediately</font> or in the short to <font color="blue">medium term rather</font>     than on funding longer-term, higher risk research and <font color="blue">development</font> projects,     time <font color="blue">commitments</font>, the cost of obtaining <font color="blue">necessary <font color="blue"><font color="blue">regulatory</font> approval</font></font> and     other costs related to <font color="blue">product innovations</font> can be substantial</td>
    </tr>
    <tr>
      <td>There can be     no  assurance  that  our <font color="blue"><font color="blue">new products</font> will <font color="blue">successfully</font> compete</font> in the     marketplace  and,  as  a result, justify the <font color="blue">expense involved</font> in their     <font color="blue">development</font> and <font color="blue"><font color="blue">regulatory</font> approval</font></td>
    </tr>
    <tr>
      <td>In addition, our <font color="blue">competitors</font> may have     developed or may in the future develop <font color="blue">new products</font> or <font color="blue">technologies</font> that     could lead to the obsolescence of one or more of our products</td>
    </tr>
    <tr>
      <td>Failure to     stay current with our <font color="blue">competitors</font> with regard to new product offerings and     <font color="blue">technological</font> changes and to <font color="blue">offer products</font> that <font color="blue">provide performance</font> that is     <font color="blue">at least comparable</font> to <font color="blue">competing products could</font> have a material adverse     effect on our business, <font color="blue">financial condition</font>, or results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If our products are not <font color="blue">accepted by</font> the market, we will not be able to     sustain or expand our business</td>
    </tr>
    <tr>
      <td>Certain of our proposed products have not yet been <font color="blue">clinically</font> tested or     <font color="blue">commercially</font> introduced, and we <font color="blue">cannot assure</font> you that any of them will     achieve  market  <font color="blue">acceptance</font> or generate operating profits</td>
    </tr>
    <tr>
      <td>We have not     <font color="blue">commercially</font> marketed many of our planned <font color="blue">new products</font>, such as certain of     our planned silicone hydrogel <font color="blue">contact lens</font> products and new <font color="blue">contact lens</font>     <font color="blue">products containing</font> our patented phosphorilcoline (PC) <font color="blue">technology</font> and have     just  begun  <font color="blue">manufacturing</font>  <font color="blue">silicone hydrogel lenses</font> in Europe</td>
    </tr>
    <tr>
      <td><font color="blue">Market     </font><font color="blue">acceptance</font>  and  <font color="blue">customer demand</font> for these products are uncertain</td>
    </tr>
    <tr>
      <td>The     <font color="blue">development</font> of a market for our products may be <font color="blue">influenced by</font> many factors,     some of which are out of our control, including:         •   <font color="blue">acceptance</font> of our <font color="blue">products by eyecare</font> and women’s healthcare     <font color="blue">practitioners</font>;         •   the cost <font color="blue">competitive</font>ness of our products;         •   <font color="blue">consumer reluctance</font> to try and use a new product;         •   <font color="blue"><font color="blue">regulatory</font> <font color="blue">requirements</font></font>;         •   the <font color="blue">earlier release</font> of <font color="blue">competitive</font> products, such as silicone hydrogel     <font color="blue">products into</font> the <font color="blue">market by</font> our <font color="blue">competitors</font>; and         •   the emergence of newer and more <font color="blue">competitive</font> products</td>
    </tr>
    <tr>
      <td>New medical and <font color="blue">technological</font> <font color="blue">development</font>s may reduce the need for our     <font color="blue">optical products</font></td>
    </tr>
    <tr>
      <td><font color="blue">Technological </font><font color="blue">development</font>s in the eyecare and women’s healthcare industries,     <font color="blue">such as new surgical procedures</font> or <font color="blue">medical devices</font>, may limit demand for our     products</td>
    </tr>
    <tr>
      <td>Corneal <font color="blue">refractive surgical procedures such as</font> Lasik surgery and     the <font color="blue">development</font> of <font color="blue">new pharmaceutical products may decrease</font> the demand for     our <font color="blue">optical products</font></td>
    </tr>
    <tr>
      <td>If these new advances were to provide a practical     <font color="blue">alternative</font> to traditional <font color="blue">vision correction</font>, the demand for <font color="blue">contact lens</font>es     and  <font color="blue">eyeglasses</font> may <font color="blue">materially</font> decrease</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> that medical     advances and <font color="blue">technological</font> <font color="blue">development</font>s will not have a material adverse     effect on our <font color="blue">businesses</font></td>
    </tr>
    <tr>
      <td>18     ______________________________________________________________________    [39]Table of <font color="blue">Contents       </font>Our  substantial and expanding <font color="blue">international</font> <font color="blue">operations</font> are subject to     <font color="blue">uncertainties</font> <font color="blue">which could</font> affect our operating results</td>
    </tr>
    <tr>
      <td>A <font color="blue">significant</font> portion of our current <font color="blue">operations</font> is conducted and located     outside the <font color="blue">United States</font>, and our <font color="blue">growth strategy</font> involves expanding our     existing foreign <font color="blue">operations</font> and entering into new foreign <font color="blue">jurisdictions</font></td>
    </tr>
    <tr>
      <td>We     have <font color="blue">significant</font> <font color="blue">manufacturing</font> and <font color="blue"><font color="blue">distribution</font> sites</font> in <font color="blue">North America </font>and     Europe</td>
    </tr>
    <tr>
      <td><font color="blue">Approximately </font>49prca and 42prca of our net sales for <font color="blue">fiscal years</font> ended     October 31, 2005 and 2004, respectively, were <font color="blue">derived from</font> the sale of     <font color="blue">products outside</font> the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>Further, we believe that <font color="blue">sales outside</font>     the <font color="blue"><font color="blue">United States</font> </font><font color="blue">will continue</font> to account for a material portion of our     <font color="blue">total net sales</font> for the <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td><font color="blue">International </font><font color="blue">operations</font> and     business  expansion  plans  are  subject to numerous <font color="blue">additional risks</font>,     including:         •   foreign <font color="blue">customers may</font> have <font color="blue">longer payment cycles than customers</font> in the     <font color="blue">United States</font>;         •   failure to <font color="blue">comply with</font> <font color="blue"><font color="blue">United States</font> </font>Department of Commerce export     controls may result in fines and/or penalties;         •   tax rates in some <font color="blue">foreign countries</font> may exceed those of the United     States, and foreign earnings may be subject to withholding <font color="blue">requirements</font> or     the imposition of tariffs, exchange controls or other <font color="blue">restrictions</font>;         •   we may find it <font color="blue">difficult</font> to <font color="blue">comply with</font> a variety of <font color="blue">foreign <font color="blue">regulatory</font></font>     <font color="blue">requirements</font>;         •   <font color="blue">general economic</font> and <font color="blue">political <font color="blue">conditions</font></font> in the countries where we     operate may have an adverse effect on our <font color="blue">operations</font> in those countries or     not be favorable to our <font color="blue">growth strategy</font>;         •   we may find it <font color="blue">difficult</font> to manage a large <font color="blue">organization spread</font>     throughout various countries;         •   <font color="blue">foreign <font color="blue">government</font>s may adopt <font color="blue">regulations</font></font> or take other actions that     would have a direct or <font color="blue">indirect <font color="blue">adverse impact on</font></font> our business and market     <font color="blue">opportunities</font>;         •   we may have <font color="blue">difficult</font>y enforcing <font color="blue"><font color="blue">agreement</font>s</font> and <font color="blue">collecting <font color="blue">receivables</font></font>     through some <font color="blue">foreign legal systems</font>;         •   <font color="blue">fluctuations</font> in <font color="blue">currency exchange rates <font color="blue">could <font color="blue">adversely</font> affect</font></font> our     results;         •   we may have <font color="blue">difficult</font>y enforcing <font color="blue"><font color="blue">intellectual</font> property</font> rights in some     <font color="blue">foreign countries</font>;         •   we may have <font color="blue">difficult</font>y gaining market share in <font color="blue">countries such as</font> Japan     because of <font color="blue">regulatory</font> <font color="blue">restrictions</font> and <font color="blue">customer preferences</font>; and         •   we may find it <font color="blue">difficult</font> to <font color="blue">enter new markets such as</font> China, India and     other developing nations due to, among other things, customer <font color="blue">acceptance</font>,     undeveloped <font color="blue">distribution</font> channels and business knowledge of these new     markets</td>
    </tr>
    <tr>
      <td>As we continue to expand our business globally, our <font color="blue">success will depend</font>, in     large part, on our ability to anticipate and <font color="blue">effective</font>ly manage these and     other <font color="blue">risks associated with</font> our <font color="blue">international</font> <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>However, any of     these <font color="blue">factors <font color="blue">could <font color="blue">adversely</font> affect</font></font> our <font color="blue">international</font> <font color="blue">operations</font> and,     <font color="blue">consequently</font>, our operating results</td>
    </tr>
    <tr>
      <td><font color="blue">Acquisitions </font>we may make <font color="blue">may involve numerous risks</font></td>
    </tr>
    <tr>
      <td>We  have  a  history  of  acquiring  <font color="blue">businesses</font> and products that have     <font color="blue">significant</font>ly contributed to our growth in <font color="blue">recent years</font>, including our     recent <font color="blue">acquisition</font> of Ocular</td>
    </tr>
    <tr>
      <td>As part of our <font color="blue">growth strategy</font>, <font color="blue">particularly</font>     at  CSI,  we  intend  to  continue to consider acquiring <font color="blue">complementary</font>     <font color="blue">technologies</font>, products and <font color="blue">businesses</font></td>
    </tr>
    <tr>
      <td>Future <font color="blue">acquisition</font>s could result in     <font color="blue">potentially dilutive issuances</font> of <font color="blue">equity securities</font>,                                           19     ______________________________________________________________________    [40]Table of <font color="blue">Contents       </font>the  incurrence  of debt and <font color="blue">contingent</font> <font color="blue">liabilities</font> and an increase in     amortization and/or write-offs of goodwill and other <font color="blue">intangible assets</font>,     <font color="blue">which could</font> have a material adverse effect upon our business, financial     condition and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Risks we <font color="blue">could face with respect</font> to     <font color="blue">acquisition</font>s include:         •   <font color="blue">difficult</font>ies in the <font color="blue">integration</font> of the <font color="blue">operations</font>, <font color="blue">technologies</font>,     products and personnel of the acquired company and <font color="blue">establishment</font> of     <font color="blue">appropriate <font color="blue">accounting</font> controls</font> and reporting procedures and other     <font color="blue"><font color="blue">regulatory</font> compliance procedures</font>;         •   risks of <font color="blue">entering markets</font> in which we have no or limited prior     experience;         •   <font color="blue">potential loss</font> of employees;         •   an <font color="blue">inability</font> to identify and consummate future <font color="blue">acquisition</font>s on favorable     terms or at all;         •   diversion of <font color="blue">management</font>’s attention away from other business concerns;         •   expenses of any undisclosed or potential <font color="blue">liabilities</font> of the acquired     company;         •   expenses, including <font color="blue">restructuring expenses</font>, to shut-down our own     locations and/or terminate our employees;         •   a dilution of <font color="blue">earnings per</font> share; and         •   <font color="blue">risks inherent</font> in <font color="blue"><font color="blue">accounting</font> allocations</font> and consequences thereof, such     as whether a strategic or <font color="blue">financial buyer would</font> view <font color="blue">such allocations as</font>     <font color="blue">establishing</font> a <font color="blue">fair value</font> for so <font color="blue">called tangible</font> and <font color="blue">intangible assets</font></td>
    </tr>
    <tr>
      <td>We face <font color="blue">risks associated with</font> <font color="blue">disruption</font> of <font color="blue">manufacturing</font> <font color="blue">operations</font> and     failure to develop new <font color="blue">manufacturing</font> processes that <font color="blue">could <font color="blue">adversely</font> affect</font>     our <font color="blue">profitability</font> or <font color="blue">competitive</font> position</td>
    </tr>
    <tr>
      <td>We <font color="blue">manufacture</font> a <font color="blue">significant</font> portion of the medical device products we sell</td>
    </tr>
    <tr>
      <td>Any <font color="blue">prolonged <font color="blue">disruption</font></font> in the <font color="blue">operations</font> of our existing <font color="blue">manufacturing</font>     <font color="blue">facilities</font>, whether due to technical or labor <font color="blue">difficult</font>ies, destruction of     or damage to any <font color="blue">facility</font> (as a result of natural disaster, use and storage     of <font color="blue">hazardous materials</font> or other events) or other reasons, could have a     material adverse effect on our business, <font color="blue">financial condition</font> and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In addition, materials, such as silicone hydrogel, require     <font color="blue">improvements</font> to our <font color="blue">manufacturing</font> processes to make them cost <font color="blue">effective</font></td>
    </tr>
    <tr>
      <td>Our     failure to develop such new <font color="blue">manufacturing</font> processes could <font color="blue">significant</font>ly     impact our ability to compete</td>
    </tr>
    <tr>
      <td>CVI <font color="blue">manufacture</font>s our molded <font color="blue">contact lens</font>es, which represent a <font color="blue">significant</font>     portion of our <font color="blue">contact lens</font> revenues, primarily at our <font color="blue">facilities</font> in the     United Kingdom, Puerto Rico and Norfolk, Virginia</td>
    </tr>
    <tr>
      <td>CSI <font color="blue">manufacture</font>s the     majority of its products in Trumbull, Connecticut</td>
    </tr>
    <tr>
      <td>We <font color="blue">manufacture</font> certain     products at only one <font color="blue">manufacturing</font> site for <font color="blue">certain markets</font>, our products     are approved for <font color="blue">manufacturing</font> only at one site</td>
    </tr>
    <tr>
      <td>Before we can use a second     <font color="blue">manufacturing</font> site we must obtain the approval of <font color="blue"><font color="blue">regulatory</font> <font color="blue">authorities</font></font> and     because this process is expensive, we have <font color="blue">generally</font> not <font color="blue">sought approvals</font>     needed to <font color="blue">manufacture</font> at an <font color="blue">additional site</font></td>
    </tr>
    <tr>
      <td>If there were any prolonged     <font color="blue">disruption</font> in the <font color="blue">operations</font> of the <font color="blue">approved <font color="blue">facility</font></font>, it could take a     <font color="blue">significant</font>  amount of time to validate a <font color="blue">second site</font> and <font color="blue">replace lost</font>     product, <font color="blue">which could</font> result in <font color="blue">lost customers</font> and <font color="blue">thereby reduce sales</font>,     <font color="blue">profitability</font> and market share</td>
    </tr>
    <tr>
      <td>If our <font color="blue">manufacturing</font> <font color="blue">operations</font> fail to <font color="blue">comply with</font> applicable <font color="blue">regulations</font>,     our <font color="blue">manufacturing</font> could be delayed or disrupted, and our <font color="blue">product sales</font> and     <font color="blue">profitability</font> <font color="blue">could suffer</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">manufacturing</font> <font color="blue">operations</font> and processes are required to <font color="blue">comply with</font>     <font color="blue">numerous federal</font>, state and foreign <font color="blue"><font color="blue">regulatory</font> <font color="blue">requirements</font></font>, including the     FDA’s Quality System Regulation, or QSR <font color="blue">regulations</font>                                           20     ______________________________________________________________________    [41]Table of <font color="blue">Contents       </font>in Japan, and other similar foreign <font color="blue">regulations</font> which govern the procedures     related to the design, testing, production processes, controls, quality     assurance, labeling, packaging, storage and shipping of our products</td>
    </tr>
    <tr>
      <td>We     also  are  subject  to  state  <font color="blue">requirements</font> and <font color="blue">licenses applicable</font> to     <font color="blue">manufacture</font>rs of <font color="blue">medical devices</font></td>
    </tr>
    <tr>
      <td>In addition, we must engage in extensive     <font color="blue">recordkeeping</font>  and reporting and must make available our <font color="blue">manufacturing</font>     <font color="blue">facilities</font> and records for <font color="blue">periodic unscheduled inspections by <font color="blue"><font color="blue">government</font>al</font></font>     agencies, including the FDA, state <font color="blue">authorities</font> and <font color="blue">comparable agencies</font> in     other countries</td>
    </tr>
    <tr>
      <td>Failure to pass a QSR or similar foreign inspection or to     <font color="blue">comply with</font> these and other applicable <font color="blue"><font color="blue">regulatory</font> <font color="blue">requirements</font></font> could result     in <font color="blue">disruption</font> of our <font color="blue">operations</font> and <font color="blue">manufacturing</font> delays in addition to,     among other things, <font color="blue">significant</font> fines, suspension of approvals, seizures or     recalls of products, operating <font color="blue">restrictions</font> and <font color="blue">criminal prosecutions</font></td>
    </tr>
    <tr>
      <td>As a     result, any failure to <font color="blue">comply with</font> applicable <font color="blue">requirements</font> could <font color="blue">adversely</font>     affect our <font color="blue">product sales</font> and <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">rely on independent suppliers</font> for <font color="blue">raw materials</font> and we could experience     <font color="blue">inventory shortages</font> if we were required to use an <font color="blue">alternative</font> supplier on     short notice</td>
    </tr>
    <tr>
      <td>We <font color="blue">rely on independent suppliers</font> for key <font color="blue">raw materials</font>, consisting primarily     of <font color="blue">various chemicals</font> and <font color="blue">packaging materials</font></td>
    </tr>
    <tr>
      <td>Raw <font color="blue">materials used by us</font> are     <font color="blue">generally</font>  available  from more <font color="blue">than one source</font></td>
    </tr>
    <tr>
      <td>However, because some     products require specialized <font color="blue">manufacturing</font> procedures, we could experience     <font color="blue">inventory shortages</font> if we were required to use an <font color="blue">alternative</font> <font color="blue">manufacture</font>r     on short notice</td>
    </tr>
    <tr>
      <td>(Asahi) is our <font color="blue">sole supplier</font> of     the material used to make our silicone hydrogel <font color="blue">contact lens</font> products,     comfilcon A If Asahi fails to supply sufficient material on a <font color="blue">timely basis</font>     or at all for any reason, we may suffer a <font color="blue">disruption</font> in the supply of our     silicone  hydrogel  <font color="blue">contact lens</font> products and may need to switch to an     <font color="blue">alternative</font>  supplier  in  <font color="blue">accordance with</font> our <font color="blue"><font color="blue">agreement</font> with</font> Asahi</td>
    </tr>
    <tr>
      <td>A     <font color="blue">disruption</font> in the supply of comfilcon A <font color="blue">could disrupt production</font> of our     silicone hydrogel <font color="blue">contact lens</font> products thereby <font color="blue">adversely</font> impacting our     ability to market and sell <font color="blue">such products</font> and our ability to compete in all     segments of the <font color="blue">contact lens</font> market</td>
    </tr>
    <tr>
      <td>We <font color="blue">face risks</font> related to <font color="blue">environment</font>al matters</td>
    </tr>
    <tr>
      <td>Our <font color="blue">facilities</font> are subject to a <font color="blue">broad range</font> of federal, state, local and     foreign <font color="blue">environment</font>al laws and <font color="blue">requirements</font>, including those governing     discharges to the air and water, the handling or disposal of solid and     <font color="blue">hazardous substances</font> and wastes and <font color="blue">remediation</font> of <font color="blue"><font color="blue">contamination</font> associated</font>     with the release of <font color="blue">hazardous substances</font> at our <font color="blue">facilities</font> and offsite     <font color="blue">disposal locations</font></td>
    </tr>
    <tr>
      <td>We have made, and <font color="blue">will continue</font> to make, <font color="blue">expenditures</font> to     <font color="blue">comply with</font> such laws and <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>Future events, such as changes in     <font color="blue">existing laws</font> and <font color="blue">regulations</font> or the <font color="blue">discovery</font> of <font color="blue"><font color="blue">contamination</font> at</font> our     <font color="blue">facilities</font>, may give rise to <font color="blue">additional compliance</font> or <font color="blue">remediation</font> costs that     could have a material adverse effect on our business, results of <font color="blue">operations</font>     or  <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>As a <font color="blue">manufacture</font>r of various products, we are     exposed to some risk of claims with respect to <font color="blue">environment</font>al matters, and     there can be no assurance that material costs or <font color="blue">liabilities</font> will not be     incurred in <font color="blue">connection</font> with any such claims</td>
    </tr>
    <tr>
      <td>We are involved in a voluntary clean-up at one of our sites in the state of     New York, and although the workplan submitted to the state was accepted and     the  clean-up  is  proceeding  in <font color="blue">accordance with</font> the workplan and our     expectations, there can be no assurance that the clean-up will be completed     within the timeframe and cost projected, that the expected results will be     achieved, or that we will not identify <font color="blue">alternate sources</font> of <font color="blue">contamination</font> in     <font color="blue">connection</font> with their <font color="blue">remediation</font></td>
    </tr>
    <tr>
      <td>As such, there can be no assurance that     material costs or <font color="blue">liabilities</font> will not be incurred in <font color="blue">connection</font> with any     such <font color="blue">remediation</font></td>
    </tr>
    <tr>
      <td>21     ______________________________________________________________________    [42]Table of <font color="blue">Contents       </font>We could experience losses from <font color="blue">product liability</font> claims, including such     claims  and other losses resulting from sales of <font color="blue">counterfeit</font> and other     <font color="blue">infringing products</font></td>
    </tr>
    <tr>
      <td>We face an inherent risk of exposure to <font color="blue">product liability</font> claims in the     event that the use of our products results in <font color="blue">personal injury</font></td>
    </tr>
    <tr>
      <td>We also face     the risk that defects in the design or <font color="blue">manufacture</font> of our products or sales     of <font color="blue">counterfeit</font> or other <font color="blue">infringing product might necessitate</font> a product     recall and other actions by <font color="blue">manufacture</font>rs, distributors or retailers in     order to safeguard the health of consumers and protect the integrity of the     subject brand</td>
    </tr>
    <tr>
      <td>In addition, consumers may halt or <font color="blue">delay purchases</font> of a     product that is the subject of a claim or recall, or has been <font color="blue">counterfeit</font>ed</td>
    </tr>
    <tr>
      <td>We handle some risk with third-party carrier policies that are subject to     <font color="blue">deductibles</font> and <font color="blue">limitations</font></td>
    </tr>
    <tr>
      <td>There can be no assurance that we will not     experience material losses due to <font color="blue">product liability</font> claims or recalls, or a     decline in sales resulting from sales of <font color="blue">counterfeit</font> or other infringing     product, in the future</td>
    </tr>
    <tr>
      <td>If we fail to <font color="blue">adequately protect</font> our <font color="blue"><font color="blue">intellectual</font> property</font>, our business     <font color="blue">could suffer</font></td>
    </tr>
    <tr>
      <td>We consider our <font color="blue"><font color="blue">intellectual</font> property</font> rights, including patents, trademarks     and <font color="blue">licensing <font color="blue"><font color="blue">agreement</font>s</font></font>, to be an integral component of our business</td>
    </tr>
    <tr>
      <td>We     attempt to protect our <font color="blue"><font color="blue">intellectual</font> property</font> rights through a <font color="blue">combination</font> of     patent, trademark, copyright and trade secret laws, as well as licensing     <font color="blue"><font color="blue">agreement</font>s</font> and third-party non<font color="blue">disclosure</font> and assignment <font color="blue"><font color="blue">agreement</font>s</font></td>
    </tr>
    <tr>
      <td>Our     failure  to obtain or maintain <font color="blue">adequate protection</font> of our <font color="blue">intellectual</font>     <font color="blue">property rights</font> for any <font color="blue">reason could</font> have a material adverse effect on our     business, results of <font color="blue">operations</font> and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>We have applied for <font color="blue">patent protection</font> in the <font color="blue"><font color="blue">United States</font> </font>and other foreign     <font color="blue">jurisdictions</font>  relating to <font color="blue">certain existing</font> and <font color="blue">proposed processes</font> and     products</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that any of our <font color="blue">patent <font color="blue"><font color="blue">application</font>s</font> will</font> be     approved</td>
    </tr>
    <tr>
      <td>Patent <font color="blue"><font color="blue">application</font>s</font> in the <font color="blue"><font color="blue">United States</font> </font>are maintained in secrecy     for a period of time, <font color="blue">which may last until patents</font> are issued, and since     <font color="blue">publication</font> of <font color="blue">discoveries</font> in the scientific or <font color="blue">patent literature tends</font> to     lag behind actual <font color="blue">discoveries</font> by several months, we cannot be certain that     we will be the first creator of <font color="blue">inventions covered by</font> any <font color="blue">patent <font color="blue">application</font></font>     we make or the first to file patent <font color="blue"><font color="blue">application</font>s</font> on such inventions</td>
    </tr>
    <tr>
      <td>The     patents we own could be challenged, invalidated or <font color="blue">circumvented by others</font>     and  may not be of <font color="blue">sufficient scope</font> or strength to <font color="blue">provide us with</font> any     <font color="blue">meaningful protection</font> or <font color="blue">commercial advantage</font></td>
    </tr>
    <tr>
      <td>Further, we <font color="blue">cannot assure</font> you     that we will have <font color="blue">adequate resources</font> to enforce our patents</td>
    </tr>
    <tr>
      <td>We also rely on unpatented <font color="blue">proprietary</font> <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>It is possible that     others  will  <font color="blue">independently</font>  develop the same or similar <font color="blue">technology</font> or     otherwise obtain access to our unpatented <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>To protect our trade     secrets  and  other  <font color="blue">proprietary</font>  information,  we  require employees,     <font color="blue">consultants</font>,  advisors and <font color="blue">collaborators</font> to <font color="blue"><font color="blue">enter into</font> confidentiality</font>     <font color="blue"><font color="blue">agreement</font>s</font></td>
    </tr>
    <tr>
      <td>We  cannot  assure you that these <font color="blue"><font color="blue">agreement</font>s</font> will provide     <font color="blue">meaningful protection</font> for our trade secrets, know-how or other <font color="blue">proprietary</font>     information  in the event of any unauthorized use, misappropriation or     <font color="blue">disclosure</font> of such trade secrets, know-how or other <font color="blue">proprietary</font> information</td>
    </tr>
    <tr>
      <td>If we are unable to maintain the <font color="blue">proprietary</font> nature of our <font color="blue">technologies</font>, we     could lose <font color="blue">competitive</font> advantages and be <font color="blue"><font color="blue">materially</font> <font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>The laws of certain <font color="blue">foreign countries</font> in which we do business or contemplate     doing business in the future do not recognize <font color="blue"><font color="blue">intellectual</font> property</font> rights     or <font color="blue">protect them</font> to the <font color="blue">same extent as</font> do the laws of the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>Adverse <font color="blue"><font color="blue">determination</font>s</font> in a judicial or <font color="blue"><font color="blue">administrative</font> proceeding could</font>     <font color="blue">prevent us from</font> <font color="blue">manufacturing</font> and selling our products or <font color="blue">prevent us from</font>     stopping others from <font color="blue">manufacturing</font> and <font color="blue">selling competing products</font>, and     thereby have a material <font color="blue">adverse affect on</font> our business, <font color="blue">financial condition</font>     and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>22     ______________________________________________________________________    [43]Table of <font color="blue">Contents       </font>Our <font color="blue"><font color="blue">intellectual</font> property</font> could be subject to claims of <font color="blue">infringement</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">competitors</font> in both the US and <font color="blue">foreign countries</font>, many of which have     <font color="blue"><font color="blue">substantially</font> greater</font> resources and have made substantial <font color="blue">investments</font> in     competing <font color="blue">technologies</font>, may have applied for or obtained, or may in the     <font color="blue">future apply</font> for and obtain, patents that will prevent, limit or otherwise     interfere  with  our ability to make and sell our existing and planned     products</td>
    </tr>
    <tr>
      <td>We have not conducted an <font color="blue">independent review</font> of <font color="blue">patents issued</font> to     <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>Claims that our <font color="blue">products infringe</font> the <font color="blue">proprietary</font> rights of     <font color="blue">others often</font> are not asserted until after <font color="blue">commencement</font> of <font color="blue">commercial sales</font>     <font color="blue">incorporating</font> our <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td><font color="blue">Significant </font><font color="blue">litigation</font> regarding <font color="blue"><font color="blue">intellectual</font> property</font> rights exists in our     industry</td>
    </tr>
    <tr>
      <td>Third parties have made, and it is possible that they will make in     future, claims of <font color="blue">infringement</font> against us or our contract <font color="blue">manufacture</font>rs in     <font color="blue">connection</font> with their use of our <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Any claims, even those without     merit, could:         •   be expensive and time consuming to defend;         •   cause us to cease making, licensing or <font color="blue">using products</font> that <font color="blue">incorporate</font>     the challenged <font color="blue"><font color="blue">intellectual</font> property</font>;         •   require us to redesign or reengineer our products, if feasible;         •   divert <font color="blue">management</font>’s attention and resources; or         •   require us to <font color="blue"><font color="blue">enter into</font> royalty</font> or <font color="blue">licensing <font color="blue"><font color="blue">agreement</font>s</font></font> in order to     obtain the right to use a <font color="blue">necessary product</font>, component or process</td>
    </tr>
    <tr>
      <td>Any royalty or <font color="blue">licensing <font color="blue"><font color="blue">agreement</font>s</font></font>, if required, may not be available to us     on acceptable terms or at all</td>
    </tr>
    <tr>
      <td>A successful claim of <font color="blue">infringement</font> against us     or our contract <font color="blue">manufacture</font>rs in <font color="blue">connection</font> with the use of our <font color="blue">technology</font>,     in particular if we are unable to <font color="blue">manufacture</font> or sell any of our planned     products in any major market, <font color="blue">could <font color="blue">adversely</font> affect</font> our business</td>
    </tr>
    <tr>
      <td>Our substantial <font color="blue">indebtedness</font> <font color="blue">could <font color="blue">adversely</font> affect</font> our <font color="blue">financial health</font> and     <font color="blue">prevent us from</font> fulfilling our <font color="blue">debt <font color="blue">obligation</font>s</font></td>
    </tr>
    <tr>
      <td>We  have  now  and  expect to continue to have a <font color="blue">significant</font> amount of     <font color="blue">indebtedness</font></td>
    </tr>
    <tr>
      <td><font color="blue">As of October </font>31, 2005, we had total <font color="blue">indebtedness</font> of dlra704dtta9     million and dlra179dtta3 million of <font color="blue"><font color="blue">availability</font> under</font> our bank credit <font color="blue">facility</font>     for <font color="blue">further borrowings</font></td>
    </tr>
    <tr>
      <td>Our substantial <font color="blue">indebtedness</font> could:         •   increase our <font color="blue">vulnerability</font> to <font color="blue">general adverse economic</font> and industry     <font color="blue">conditions</font>;         •   require us to dedicate a substantial portion of our <font color="blue">cash flow</font> from     <font color="blue">operations</font> to <font color="blue">payments on</font> our <font color="blue">indebtedness</font>, thereby reducing the     <font color="blue">availability</font> of our <font color="blue">cash flow</font> to fund working capital, capital <font color="blue">expenditures</font>,     <font color="blue">acquisition</font>s, research and <font color="blue">development</font> efforts and other <font color="blue">general corporate</font>     purposes;         •   limit our <font color="blue">flexibility</font> in planning for, or reacting to, changes in our     business and the industry in which we operate;         •   place us at a <font color="blue">competitive</font> disadvantage compared to our <font color="blue">competitors</font> that     have less debt;         •   limit our ability to <font color="blue">borrow additional funds</font>; and                                           23     ______________________________________________________________________    [44]Table of <font color="blue">Contents       </font>•   make it more <font color="blue">difficult</font> for us to satisfy our <font color="blue">obligation</font>s with respect to     our debt, including our <font color="blue">obligation</font> to repay our credit <font color="blue">facility</font> or     repurchase the <font color="blue">debentures</font> under certain circumstances;         In addition, our credit <font color="blue">facility</font> contains financial and other <font color="blue">restrictive</font>     covenants that will limit our ability to engage in <font color="blue">activities</font> that may be in     our long-term best interests</td>
    </tr>
    <tr>
      <td>Our failure to <font color="blue">comply with</font> those covenants     could result in an event of <font color="blue">default which</font>, if not cured or waived, could     result in the <font color="blue">acceleration</font> of all of our debt</td>
    </tr>
    <tr>
      <td>We are vulnerable to <font color="blue"><font color="blue">interest rate risk</font> with respect</font> to our debt</td>
    </tr>
    <tr>
      <td>We are subject to <font color="blue">interest rate risk</font> in <font color="blue">connection</font> with the issuance of     variable  and fixed-rate debt</td>
    </tr>
    <tr>
      <td>In order to maintain our desired mix of     fixed-rate and variable-rate debt, we may use interest rate swap <font color="blue"><font color="blue">agreement</font>s</font>     and exchange fixed and variable-rate interest payment <font color="blue">obligation</font>s over the     life of the arrangements, without exchange of the <font color="blue">underlying principal</font>     amounts</td>
    </tr>
    <tr>
      <td>We may not be successful in structuring such swap <font color="blue"><font color="blue">agreement</font>s</font> to     <font color="blue">effective</font>ly manage our risks, <font color="blue">which could</font> <font color="blue">adversely</font> affect our business,     earnings and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>Exchange rate <font color="blue">fluctuations</font> <font color="blue">could <font color="blue">adversely</font> affect</font> our financial results</td>
    </tr>
    <tr>
      <td>As  a  result  of our <font color="blue">international</font> <font color="blue">operations</font>, currency exchange rate     <font color="blue">fluctuations</font>  tend  to  affect our results of <font color="blue">operations</font> and financial     position</td>
    </tr>
    <tr>
      <td>Our most <font color="blue">significant</font> currency exposures are the British Pound,     Canadian Dollar, Japanese Yen, and Euro</td>
    </tr>
    <tr>
      <td>We expect to generate an increasing     portion of our revenue and incur a <font color="blue">significant</font> portion of our expenses in     currencies other than US dollars</td>
    </tr>
    <tr>
      <td>Although we <font color="blue">may <font color="blue">enter into</font> foreign</font>     exchange <font color="blue"><font color="blue">agreement</font>s</font> with financial institutions to reduce our exposure to     <font color="blue">fluctuations</font> in <font color="blue">foreign currency values relative</font> to our debt or <font color="blue">receivables</font>     <font color="blue">obligation</font>s, these <font color="blue">hedging <font color="blue">transactions</font></font>, if entered into, will not eliminate     that  <font color="blue">risk entirely</font></td>
    </tr>
    <tr>
      <td>In addition, to the extent we are unable to match     revenue received in <font color="blue">foreign currencies with costs paid</font> in the <font color="blue">same currency</font>,     exchange rate <font color="blue">fluctuations</font> could have a <font color="blue">negative impact on</font> our financial     condition and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Additionally, because our <font color="blue">consolidated</font>     financial results are reported in dollars, if we <font color="blue">generate sales</font> or earnings     in other currencies the <font color="blue">translation</font> of those results <font color="blue">into dollars</font> can result     in  a <font color="blue">significant</font> increase or decrease in the amount of those sales or     earnings</td>
    </tr>
    <tr>
      <td>We may be required to recognize <font color="blue">impairment</font> charges on goodwill, which would     reduce our <font color="blue">consolidated</font> net worth and stockholders’ equity</td>
    </tr>
    <tr>
      <td>Pursuant to <font color="blue">generally</font> accepted <font color="blue">accounting</font> principles in the <font color="blue">United States</font>,     we are required to perform <font color="blue"><font color="blue">impairment</font> tests on</font> our <font color="blue">goodwill balance annually</font>     or  at any time when events occur, <font color="blue">which could</font> impact the value of our     business segments</td>
    </tr>
    <tr>
      <td>Our <font color="blue">determination</font> of whether an <font color="blue">impairment</font> has occurred     is <font color="blue">based on</font> a <font color="blue">comparison</font> of each of our reporting units’ fair market value     with its carrying value</td>
    </tr>
    <tr>
      <td><font color="blue">Significant </font>and <font color="blue">unanticipated</font> changes could require     a provision for <font color="blue">impairment</font> in a <font color="blue">future period</font> that <font color="blue">could <font color="blue">substantially</font></font>     affect our reported earnings in a period of such change</td>
    </tr>
    <tr>
      <td>In addition, such     charges  would reduce our <font color="blue">consolidated</font> net worth and our <font color="blue">shareholders</font>’     equity, increasing our debt to total capitalization ratio, which may result     in a <font color="blue">default under</font> our credit <font color="blue">facilities</font></td>
    </tr>
    <tr>
      <td><font color="blue">Increases </font>in our <font color="blue">effective</font> tax rates or adverse outcomes resulting from     <font color="blue">examination</font> of <font color="blue">income tax returns</font> for Ocular Sciences, Inc</td>
    </tr>
    <tr>
      <td>for periods     prior to our <font color="blue">acquisition</font> <font color="blue">could <font color="blue">adversely</font> affect</font> our results</td>
    </tr>
    <tr>
      <td>Our future <font color="blue">effective</font> tax rates could be <font color="blue">adversely</font> affected by earnings being     <font color="blue">higher than</font> anticipated in countries where the company has <font color="blue">higher statutory</font>     rates or lower than anticipated in countries where it                                           24     ______________________________________________________________________    [45]Table of <font color="blue">Contents       </font>has lower statutory rates, by changes in valuation of our <font color="blue">deferred tax</font>     assets and <font color="blue">liabilities</font>, or by changes in tax laws or <font color="blue">interpretations</font> of     those laws</td>
    </tr>
    <tr>
      <td>In addition, the <font color="blue">Internal Revenue Service </font>has <font color="blue">been auditing</font>     Ocular’s <font color="blue">income tax returns</font> for the years 1999 – 2003, and we are also     subject  to  the  <font color="blue">examination</font>  of  its <font color="blue">income tax returns</font> by other tax     <font color="blue">authorities</font></td>
    </tr>
    <tr>
      <td>The outcome of these <font color="blue">examination</font>s could have a material adverse     effect on our operating results and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>We are in the process of <font color="blue">upgrading certain</font> of our <font color="blue">management</font> information     systems and we <font color="blue">cannot assure</font> you that <font color="blue">there will</font> not be <font color="blue">associated excessive</font>     costs or <font color="blue">disruption</font> of our business</td>
    </tr>
    <tr>
      <td>We have implemented a <font color="blue">management</font> information system at our <font color="blue">major locations</font>     and are in the process of <font color="blue">implementing</font> the system for <font color="blue">substantially</font> all of     our <font color="blue">businesses</font> worldwide</td>
    </tr>
    <tr>
      <td>Many other companies have had severe problems with     computer system <font color="blue">implementations</font> of this nature and scope</td>
    </tr>
    <tr>
      <td>We are using a     controlled project plan, and we believe we have <font color="blue">assigned adequate staffing</font>     and other resources to the projects to ensure its <font color="blue">successful implementation</font></td>
    </tr>
    <tr>
      <td>However, we <font color="blue">cannot assure</font> you that the <font color="blue">design will meet</font> our current and     future business needs or that it will operate as designed</td>
    </tr>
    <tr>
      <td>We are heavily     <font color="blue">dependent on such computer systems</font>, and any failure or delay in the system     <font color="blue">implementation would</font> cause a substantial <font color="blue">interruption</font> to our business,     <font color="blue">additional expense</font> and loss of sales, customers and profits</td>
    </tr>
    <tr>
      <td>If we do not retain our <font color="blue">key personnel</font> and attract and retain other highly     <font color="blue">skilled employees</font> our business <font color="blue">could suffer</font></td>
    </tr>
    <tr>
      <td>If we fail to recruit and retain the <font color="blue">necessary personnel</font>, our business and     our  ability to obtain <font color="blue">new customers</font>, develop <font color="blue">new products</font> and provide     acceptable levels of customer service <font color="blue">could suffer</font></td>
    </tr>
    <tr>
      <td>The success of our     business  is <font color="blue">heavily dependent on</font> the <font color="blue">leadership</font> of our key <font color="blue">management</font>     personnel</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success also depends on</font> our ability to recruit, retain and     motivate  highly  skilled  sales, marketing and <font color="blue">engineering personnel</font></td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>for these persons in our industry is intense and we may not be     able to <font color="blue">successfully</font> recruit, train or retain qualified personnel</td>
    </tr>
    <tr>
      <td><font color="blue">Provisions </font>of our governing <font color="blue">documents</font> and Delaware law, and our rights plan,     may have anti-takeover effects</td>
    </tr>
    <tr>
      <td>Certain provisions of our <font color="blue">Second Restated Certificate of Incorporation </font>and     Amended and Restated By-laws may inhibit changes in control of the <font color="blue">Company     </font>not  approved  by  our  board  of <font color="blue">directors</font></td>
    </tr>
    <tr>
      <td>These provisions include:     (i) advance notice <font color="blue">requirements</font> for <font color="blue">stockholder proposals</font> and <font color="blue">nominations</font>     and (ii) the authority of our board to <font color="blue">issue without stockholder approval</font>     <font color="blue">preferred stock with such terms as</font> our <font color="blue">board may</font> determine</td>
    </tr>
    <tr>
      <td>We will also be     afforded the <font color="blue">protections</font> of Section 203 of the Delaware General Corporation     Law, <font color="blue">which could</font> have similar effects</td>
    </tr>
    <tr>
      <td>Our board of <font color="blue">directors</font> adopted a     <font color="blue">preferred stock purchase rights</font> plan, <font color="blue">commonly known as</font> a “<font color="blue">poison pill</font>,”     pursuant to a <font color="blue">rights <font color="blue">agreement</font> dated as</font> of October 29, 1997</td>
    </tr>
    <tr>
      <td>The rights     <font color="blue">agreement</font>  is intended to <font color="blue">prevent abusive hostile takeover attempts by</font>     requiring a <font color="blue">potential acquiror</font> to negotiate the terms of an <font color="blue">acquisition</font> with     our board of <font color="blue">directors</font></td>
    </tr>
    <tr>
      <td>However, it could have the effect of deterring or     preventing an <font color="blue">acquisition</font> of our company, even if a majority of the our     <font color="blue">stockholders would</font> be in favor of such <font color="blue">acquisition</font>, and <font color="blue">could also</font> have the     effect of making it more <font color="blue">difficult</font> for a person or group to <font color="blue">gain control</font> of     the Company or to change existing <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>25     ______________________________________________________________________    [46]Table of <font color="blue">Contents       </font>Risks Relating to Government Regulation of Manufacture and Sale of Our     Products          Our failure to <font color="blue">comply with</font> <font color="blue"><font color="blue">regulatory</font> <font color="blue">requirements</font></font> or to receive <font color="blue">regulatory</font>     clearance or approval for our products or <font color="blue"><font color="blue">operations</font> could</font> <font color="blue">adversely</font> affect     our business</td>
    </tr>
    <tr>
      <td>Our products and <font color="blue">operations</font> are subject to <font color="blue">rigorous regulation by</font> the FDA,     and numerous other federal, state and foreign <font color="blue"><font color="blue">government</font>al</font> <font color="blue">authorities</font></td>
    </tr>
    <tr>
      <td>In     the <font color="blue">United States</font>, the FDA <font color="blue">regulates virtually</font> all aspects of a medical     device’s testing, <font color="blue">manufacture</font>, safety, labeling, storage, <font color="blue">recordkeeping</font>,     reporting, marketing, promotion and <font color="blue">distribution</font>, as well as the export of     <font color="blue">medical devices</font> <font color="blue">manufacture</font>d in the <font color="blue"><font color="blue">United States</font> </font>to foreign markets</td>
    </tr>
    <tr>
      <td>Our     failure to <font color="blue">comply with</font> FDA <font color="blue">regulations</font> could lead to the imposition of     <font color="blue">administrative</font> or <font color="blue">judicial sanctions</font>, including injunctions, suspensions or     the  loss  of  <font color="blue">regulatory</font>  approvals,  product recalls, termination of     <font color="blue">distribution</font>, or <font color="blue">product seizures</font></td>
    </tr>
    <tr>
      <td>In the most <font color="blue">egregious</font> cases, criminal     sanctions or closure of our <font color="blue">manufacturing</font> <font color="blue">facilities</font> are possible</td>
    </tr>
    <tr>
      <td>Our <font color="blue">medical devices</font> require clearance or <font color="blue">approval by</font> the FDA before they can     be <font color="blue">commercially</font> distributed in the <font color="blue"><font color="blue">United States</font> </font>and may require similar     approvals by <font color="blue">foreign <font color="blue">regulatory</font></font> agencies before <font color="blue">distribution</font> in foreign     <font color="blue">jurisdictions</font></td>
    </tr>
    <tr>
      <td>The process of obtaining <font color="blue"><font color="blue">regulatory</font> approval</font>s to market a     medical device, <font color="blue"><font color="blue">particularly</font> from</font> the FDA, can be costly and time consuming</td>
    </tr>
    <tr>
      <td>There can be no assurance that <font color="blue">such approvals will</font> be <font color="blue">granted on</font> a timely     basis, if at all, or that <font color="blue">significant</font> delays in the <font color="blue">introduction</font> of any new     products or <font color="blue">product <font color="blue">enhancements</font> will</font> not occur, <font color="blue">which could</font> <font color="blue">adversely</font>     affect our <font color="blue">competitive</font> position and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Modifications </font>and <font color="blue">enhancements</font> to a medical device also require a new FDA     clearance or approval if they could <font color="blue">significant</font>ly affect its safety or     <font color="blue">effective</font>ness or <font color="blue">would constitute</font> a major change in its intended use, design     or  <font color="blue">manufacture</font></td>
    </tr>
    <tr>
      <td>The  FDA  requires  every  <font color="blue">manufacture</font>r to make this     <font color="blue">determination</font>  in  the  first  instance,  but  the  FDA may review any     <font color="blue">manufacture</font>r’s decision</td>
    </tr>
    <tr>
      <td>We have made <font color="blue"><font color="blue">modification</font>s</font> and <font color="blue">enhancements</font> to our     medical  devices  that  we  do  not believe require a new clearance or     <font color="blue">application</font>,  but  we  <font color="blue">cannot confirm</font> that the FDA <font color="blue">will agree with</font> our     <font color="blue">decisions</font></td>
    </tr>
    <tr>
      <td>If  the  FDA requires us to <font color="blue">seek clearance</font> or approval for     <font color="blue">modification</font> of a <font color="blue">previously cleared product</font> for which we have concluded     that <font color="blue">new clearances</font> or approvals are <font color="blue">unnecessary</font>, we may be required to     <font color="blue">cease marketing</font> or to recall the <font color="blue">modified product until</font> we obtain clearance     or  approval, and we may be subject to <font color="blue">significant</font> <font color="blue">regulatory</font> fines or     penalties, <font color="blue">which could</font> have a material adverse effect on our financial     results and <font color="blue">competitive</font> position</td>
    </tr>
    <tr>
      <td>Even if <font color="blue"><font color="blue">regulatory</font> approval</font> or clearance of a medical device is granted, the     FDA may impose <font color="blue">limitations</font> or <font color="blue">restrictions</font> on the uses and indications for     which the device may be labeled and promoted, and failure to <font color="blue">comply with</font> FDA     <font color="blue">regulations</font>  prohibiting a <font color="blue">manufacture</font>r from promoting a device for an     unapproved, or “off-label” use could result in <font color="blue">enforcement action by</font> the     FDA, including, among other things, warning letters, fines, injunctions,     <font color="blue">consent decrees</font>, and civil or <font color="blue">criminal penalties</font></td>
    </tr>
    <tr>
      <td><font color="blue">Development </font>and marketing of our products is subject to strict <font color="blue"><font color="blue">government</font>al</font>     regulation by <font color="blue">foreign <font color="blue">regulatory</font></font> agencies, and failure to receive, or delay     in receiving, foreign <font color="blue">qualifications</font> could have a material <font color="blue">adverse affect on</font>     our business</td>
    </tr>
    <tr>
      <td>In many of the <font color="blue">foreign countries</font> in which we market our products, we are     subject to <font color="blue">regulations</font> affecting, among other things, product standards,     packaging <font color="blue">requirements</font>, labeling <font color="blue">requirements</font>, import <font color="blue">restrictions</font>, tariff     <font color="blue">regulations</font>, duties and tax <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>Many of the <font color="blue">regulations</font> applicable     to our devices and products in <font color="blue">such countries</font> are similar to those of the     FDA In many countries, the <font color="blue">national health</font> or <font color="blue">social security organizations</font>     require our products to be qualified before they can be                                           26     ______________________________________________________________________    [47]Table of <font color="blue">Contents       </font><font color="blue">marketed with</font> the benefit of <font color="blue"><font color="blue">reimbursement</font> <font color="blue">eligibility</font></font></td>
    </tr>
    <tr>
      <td>To date, we have not     experienced <font color="blue">difficult</font>y in <font color="blue">complying with</font> these <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>Due to the     <font color="blue">movement towards <font color="blue">harmonization</font></font> of standards in the European Union, we expect     a changing <font color="blue">regulatory</font> <font color="blue">environment</font> in Europe <font color="blue">characterized by</font> a shift from a     country  by-country  <font color="blue">regulatory</font> system to a European Union-wide single     <font color="blue">regulatory</font>  system</td>
    </tr>
    <tr>
      <td>We  cannot  currently  predict the timing of this     <font color="blue">harmonization</font></td>
    </tr>
    <tr>
      <td>Our failure to receive, or delays in the receipt of, relevant     foreign <font color="blue">qualifications</font> could have a material adverse effect on our business,     <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our products are subject to reporting <font color="blue">requirements</font> and recalls, even after     receiving <font color="blue">regulatory</font> clearance or approval, <font color="blue">which could</font> harm our reputation,     business and financial results</td>
    </tr>
    <tr>
      <td>After a device is placed on the market, numerous <font color="blue"><font color="blue">regulatory</font> <font color="blue">requirements</font></font>     apply, including the FDA’s Quality System Regulation, or QSR, which requires     <font color="blue">manufacture</font>rs to follow design, testing, control, documentation and other     <font color="blue">quality assurance procedures during</font> the <font color="blue">manufacturing</font> process; labeling     <font color="blue">regulations</font>, which prohibit the promotion of products for unapproved or     “off-label” uses and impose other <font color="blue">restrictions</font> on labeling; and medical     device reporting <font color="blue">regulations</font> that require us to report to FDA or similar     <font color="blue"><font color="blue">government</font>al</font> bodies in other countries if our products cause or contribute     to  a  death  or  <font color="blue">serious injury</font> or <font color="blue">malfunction</font> in a way that would be     <font color="blue">reasonably</font>  likely  to  contribute  to  death or <font color="blue">serious injury</font> if the     <font color="blue">malfunction</font> were to recur</td>
    </tr>
    <tr>
      <td>The FDA and similar <font color="blue"><font color="blue">government</font>al</font> bodies in other     countries have the authority to require the recall of our products in the     event  of material <font color="blue">deficiencies</font> or defects in design or <font color="blue">manufacture</font></td>
    </tr>
    <tr>
      <td>A     <font color="blue"><font color="blue">government</font> mandated</font> or <font color="blue">voluntary recall by us could</font> occur as a result of     <font color="blue">manufacturing</font>  or  <font color="blue">labeling errors</font> or <font color="blue">design defects</font></td>
    </tr>
    <tr>
      <td>Any voluntary or     <font color="blue"><font color="blue">government</font> mandated</font> recall may divert <font color="blue">management</font> attention and financial     resources and harm our <font color="blue">reputation with customers</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">recall involving one</font>     of  our products <font color="blue">could also</font> harm the reputation of the product and the     Company and would be <font color="blue">particularly</font> harmful to our business and financial     results</td>
    </tr>
    <tr>
      <td>Changes in <font color="blue">government</font> regulation of the <font color="blue">retail optical industry</font> or in the     selling and <font color="blue">prescribing practices</font> for <font color="blue">contact lens</font>es could have a material     <font color="blue">adverse impact on</font> our business and financial results</td>
    </tr>
    <tr>
      <td>Our  success  depends  to a <font color="blue">significant</font> extent upon the success of our     customers who prescribe and fit <font color="blue">contact lens</font>es, including <font color="blue">optometrists</font>,     <font color="blue">ophthalmologists</font>, and optical retail outlets, which are subject to a variety     of  federal,  state  and local laws, <font color="blue">regulations</font> and ordinances</td>
    </tr>
    <tr>
      <td><font color="blue">These     </font><font color="blue">regulations</font> relate to who is permitted to prescribe and fit <font color="blue">contact lens</font>es,     the prescriber’s <font color="blue">obligation</font> to <font color="blue">provide <font color="blue">prescription</font>s</font> to its patients, the     length  of  time a <font color="blue">prescription</font> is valid, the ability or <font color="blue">obligation</font> of     <font color="blue">prescribers</font> to <font color="blue">prescribe lenses by</font> brand <font color="blue">rather than by generic equivalent</font>     or <font color="blue">specification</font>, and other matters</td>
    </tr>
    <tr>
      <td>The state and local legal <font color="blue">requirements</font>     vary widely among <font color="blue">jurisdictions</font> and are subject to frequent change</td>
    </tr>
    <tr>
      <td>In addition, numerous healthcare-related <font color="blue">legislative</font> proposals have been     made in <font color="blue">recent years</font> in the <font color="blue">Congress </font>and in various state <font color="blue">legislatures</font></td>
    </tr>
    <tr>
      <td>For     instance, the Fairness to Contact Lens Consumers Act, which was <font color="blue">enacted on</font>     <font color="blue">December </font>6, 2003, requires that <font color="blue">contact lens</font> <font color="blue">prescribers</font> provide patients     with a copy of their <font color="blue">contact lens</font> <font color="blue">prescription</font>s after a <font color="blue">contact lens</font> fitting     and verify those <font color="blue">prescription</font>s to any <font color="blue">third party designated by</font> a patient,     such as an <font color="blue">online seller</font></td>
    </tr>
    <tr>
      <td>Further <font color="blue">legislative</font> or <font color="blue">policy initiatives directed</font>     at <font color="blue">prescribers</font> and the <font color="blue">retail optical industry</font> could be <font color="blue">introduced on either</font>     the federal or state level</td>
    </tr>
    <tr>
      <td>The <font color="blue">potential impact</font> of these proposals with     respect to the business of our customers is uncertain, and we <font color="blue">cannot assure</font>     you that that the proposals, if adopted, would not have a material adverse     impact  on  our revenues, business, <font color="blue">financial condition</font> and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>27     ______________________________________________________________________    [48]Table of <font color="blue">Contents       </font>Adverse <font color="blue">regulatory</font> or other <font color="blue">decisions</font> affecting eyecare <font color="blue">practitioners</font>, or     material  changes in the selling and <font color="blue">prescribing practices</font> for contact     lenses, <font color="blue">could also</font> have a material <font color="blue">adverse affect on</font> our business, operating     results and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>Finally, <font color="blue">although cost controls</font> or other     <font color="blue">requirements</font> imposed by third party healthcare payors, such as insurers and     <font color="blue">health maintenance organizations</font>, have not <font color="blue">historically</font> had a <font color="blue">significant</font>     effect on <font color="blue">contact lens</font> prices or <font color="blue">distribution</font> practices, this could change     in the future and <font color="blue">could <font color="blue">adversely</font> affect</font> our business, <font color="blue">financial condition</font>     and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Changes in <font color="blue">government</font> regulation of the <font color="blue">healthcare industry</font> could <font color="blue">materially</font>     <font color="blue">adversely</font> affect our business</td>
    </tr>
    <tr>
      <td>In <font color="blue">recent years</font>, an increasing number of <font color="blue">legislative</font> initiatives have been     introduced or proposed in <font color="blue">Congress </font>and in state <font color="blue">legislatures</font> that could     effect major changes in the healthcare system, either nationally or at the     state level</td>
    </tr>
    <tr>
      <td>Among the proposals under <font color="blue">consideration</font> are price controls on     hospitals, insurance market reforms to increase the <font color="blue">availability</font> of group     health insurance to small <font color="blue">businesses</font>, <font color="blue">requirements</font> that all <font color="blue">businesses</font> offer     health  insurance  coverage  to  their employees and the creation of a     <font color="blue">government</font> health insurance plan or plans that <font color="blue">would cover</font> all citizens</td>
    </tr>
    <tr>
      <td>There continue to be <font color="blue">efforts at</font> the <font color="blue">federal level</font> to <font color="blue">introduce various</font>     insurance  market  reforms, expanded fraud and abuse and <font color="blue">anti referral</font>     <font color="blue">legislation</font> and <font color="blue">further reductions</font> in <font color="blue">Medicare and Medicaid </font>coverage and     <font color="blue">reimbursement</font></td>
    </tr>
    <tr>
      <td>A  broad  range of both similar and more <font color="blue">comprehensive</font>     <font color="blue">healthcare reform initiatives</font> is likely to be considered at the state level</td>
    </tr>
    <tr>
      <td>It is <font color="blue">uncertain which</font>, if any, of these or other <font color="blue">proposals will</font> be adopted</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot predict</font> the effect <font color="blue">such reforms</font> or the prospect of their <font color="blue">enactment</font>     may have on our business</td>
    </tr>
    <tr>
      <td>The costs of <font color="blue">complying with</font> the <font color="blue">requirements</font> of <font color="blue">federal laws pertaining</font> to     the privacy and security of health information and the <font color="blue">potential liability</font>     <font color="blue">associated with failure</font> to do so could <font color="blue">materially</font> <font color="blue">adversely</font> affect our     business and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Other  federal  <font color="blue">legislation</font> will affect the manner in which we use and     disclose  health  information</td>
    </tr>
    <tr>
      <td>The  Health  Insurance Portability and     Accountability  Act  of 1996 (HIPAA) mandates, among other things, the     adoption of standards for the <font color="blue"><font color="blue">electronic</font> exchange</font> of health information that     may require <font color="blue">significant</font> and costly changes to <font color="blue">current practices</font></td>
    </tr>
    <tr>
      <td>The US     Department of Health and Human Services (HHS) has <font color="blue">released three rules</font> to     <font color="blue">date mandating</font> the use of <font color="blue">new standards with respect</font> to <font color="blue">certain healthcare</font>     <font color="blue">transactions</font> and health information</td>
    </tr>
    <tr>
      <td>The <font color="blue">first rule</font> requires the use of     <font color="blue">uniform standards</font> for common healthcare <font color="blue">transactions</font>, including healthcare     claims  information,  plan  <font color="blue">eligibility</font>,  referral  <font color="blue">certification</font>  and     <font color="blue">authorization</font>, claims status, plan <font color="blue">enrollment</font> and dis<font color="blue">enrollment</font>, payment and     <font color="blue">remittance advice</font>, plan <font color="blue">premium payments</font>, and <font color="blue">coordination</font> of benefits</td>
    </tr>
    <tr>
      <td>The     <font color="blue">second rule <font color="blue">released by</font></font> HHS <font color="blue">imposes new standards</font> relating to the privacy of     <font color="blue">individually identifiable health</font> information</td>
    </tr>
    <tr>
      <td>These standards not only     require <font color="blue"><font color="blue">compliance with</font> rules governing</font> the use and <font color="blue">disclosure</font> of protected     health information, but they also require an entity subject to HIPAA to     obtain satisfactory assurances that any of its business <font color="blue">associates</font> to whom     such information is disclosed <font color="blue">will safeguard</font> the information</td>
    </tr>
    <tr>
      <td>The third rule     <font color="blue">released by</font> HHS <font color="blue">establishes minimum standards</font> for the security of <font color="blue">electronic</font>     health information</td>
    </tr>
    <tr>
      <td>While we do not believe we are <font color="blue">directly regulated as</font> a     covered entity under HIPAA, many of our customers are <font color="blue">covered entities</font>     subject to <font color="blue">HIPAA Such </font><font color="blue">customers may</font> require us to <font color="blue">enter into</font> business     <font color="blue">associates</font>  <font color="blue"><font color="blue">agreement</font>s</font>,  which obligate us to <font color="blue">safeguard certain health</font>     information we obtain in the course of servicing the customers, restrict the     manner in which we use and disclose such information and <font color="blue">impose liability on</font>     us for failure to meet our contractual <font color="blue">obligation</font>s</td>
    </tr>
    <tr>
      <td>The costs of complying     with these contractual <font color="blue">obligation</font>s and <font color="blue">potential liability</font> associated with     failure to do so could have a material adverse effect on our business and     <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>28     ______________________________________________________________________    [49]Table of <font color="blue">Contents       </font>Federal  and state laws pertaining to healthcare fraud and abuse could     <font color="blue">materially</font> <font color="blue">adversely</font> affect our business and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We may be subject to <font color="blue">various federal</font> and state laws pertaining to healthcare     fraud and abuse, including anti-kickback laws and physician self-referral     laws</td>
    </tr>
    <tr>
      <td><font color="blue">Violations  </font>of  these laws are punishable by criminal and civil     sanctions, including, in some instances, exclusion from <font color="blue">participation</font> in     federal  and  state healthcare programs, including Medicare, Medicaid,     Veterans Administration <font color="blue">health programs</font> and <font color="blue">TRICARE While </font>we believe that     our <font color="blue">operations</font> are in material <font color="blue">compliance with</font> such laws, because of the     complex and far-reaching nature of these laws, there can be no assurance     that we would not be required to alter one or more of its practices to be in     <font color="blue">compliance with</font> these laws</td>
    </tr>
    <tr>
      <td>Any violations of these laws or <font color="blue">regulations</font>     could  result  in a material adverse effect on our business, financial     condition and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In addition, if there is a change in     law, regulation, <font color="blue">administrative</font> or <font color="blue">judicial interpretation</font>, we may have to     change our business practices or our existing business <font color="blue">practices could</font> be     challenged as unlawful, <font color="blue">which could</font> have a material adverse effect on our     business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
  </tbody>
</table>